Embed

Academic

Authors

Mitchell A. Nides

Mitchell A. Nides,University of California Los Angeles,Psychiatry & Psychology,Diseases,Pharmacology

Edit

Mitchell A. Nides

University of California Los Angeles

Publications: 37 | Citations: 2194

Fields: Psychiatry & Psychology, Diseases, Pharmacology

Collaborated with 131 co-authors from 1989 to 2008 | Cited by 4556 authors

Cumulative Annual

Sort by:

Publications (37)

BibTeX | RIS | RefWorks Download

Update on Pharmacologic Options for Smoking Cessation Treatment (Citations: 30)

Journal: American Journal of Medicine - AMER J MED , vol. 121, no. 4, pp. S20-S31, 2008

Maximizing Smoking Cessation in Clinical Practice: Pharmacologic and Behavioral Interventions (Citations: 4)

, , ,

Journal: Preventive Cardiology , vol. 10, no. s2, pp. 23-30, 2007

Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell®) (Citations: 1)

, , ,

Journal: BMC Clinical Pharmacology - BMC Clin Pharmacol , vol. 7, no. 1, pp. 11-15, 2007

Varenicline, an 4beta2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial (Citations: 282)

, , , , , , , , ,

Journal: Jama-journal of The American Medical Association - JAMA-J AM MED ASSN , vol. 296, no. 1, pp. 47-55, 2006

Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking Cessation (Citations: 69)

, , , , , , ,

Published in 2006.

Sort by:

Citations (2194 times by 1510 publications)

A Review of Smoking Cessation in Bipolar Disorder: Implications for Future Research (Citations: 2)

, ,

Journal: Journal of Dual Diagnosis , vol. just-accep, no. just-accep, 2012

Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12Week, Open-Label Trial (Citations: 2)

, , , , , , , , , , ,

Journal: Journal of Dual Diagnosis , vol. just-accep, no. just-accep, 2012

Varenicline Should Be Used as a First-Line Treatment to Help Smokers With Mental Illness Quit (Citations: 1)

Journal: Journal of Dual Diagnosis , vol. just-accep, no. just-accep, 2012

Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=56650651&selfId1=23516739&selfId2=0&maxNumber=12&query=

Journal: Neuropsychopharmacology , vol. 37, no. 3, pp. 660-668, 2012

How Do Perceptions About Cessation Outcomes Moderate the Effectiveness of a Gain-Framed Smoking Cessation Telephone Counseling Intervention?

, , , , , , , ,

Journal: Journal of Health Communication - J HEALTH COMMUN , vol. ahead-of-p, no. ahead-of-p, pp. 1-18, 2012

Comments

Co-authors (131)

Journals (22)

Keywords (38)

Mitchell A. Nides,University of California Los Angeles,Psychiatry & Psychology,Diseases,Pharmacology

Publications (37)

BibTeX | RIS | RefWorks Download

Update on Pharmacologic Options for Smoking Cessation Treatment (Citations: 30)

Maximizing Smoking Cessation in Clinical Practice: Pharmacologic and Behavioral Interventions (Citations: 4)

Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell®) (Citations: 1)

Varenicline, an 4beta2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial (Citations: 282)

Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking Cessation (Citations: 69)

Citations (2194 times by 1510 publications)

A Review of Smoking Cessation in Bipolar Disorder: Implications for Future Research (Citations: 2)

Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12Week, Open-Label Trial (Citations: 2)

Varenicline Should Be Used as a First-Line Treatment to Help Smokers With Mental Illness Quit (Citations: 1)

Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial

How Do Perceptions About Cessation Outcomes Moderate the Effectiveness of a Gain-Framed Smoking Cessation Telephone Counseling Intervention?


	View FAQ about top research areas and Fields of study

Co-authors (131)

Journals (22)

Keywords (38)

Mitchell A. Nides,University of California Los Angeles,Psychiatry & Psychology,Diseases,Pharmacology

Publications (37) BibTeX | RIS | RefWorks Download

Update on Pharmacologic Options for Smoking Cessation Treatment (Citations: 30)

Maximizing Smoking Cessation in Clinical Practice: Pharmacologic and Behavioral Interventions (Citations: 4)

Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell®) (Citations: 1)

Varenicline, an 4beta2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial (Citations: 282)

Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking Cessation (Citations: 69)

Citations (2194 times by 1510 publications)

A Review of Smoking Cessation in Bipolar Disorder: Implications for Future Research (Citations: 2)

Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12Week, Open-Label Trial (Citations: 2)

Varenicline Should Be Used as a First-Line Treatment to Help Smokers With Mental Illness Quit (Citations: 1)

Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial

How Do Perceptions About Cessation Outcomes Moderate the Effectiveness of a Gain-Framed Smoking Cessation Telephone Counseling Intervention?

Publications (37)

BibTeX | RIS | RefWorks Download